4103results about "Antimycotics" patented technology

The invention provides a broad-spectrum antibacterial peptide, an antibacterial agent and application, and belongs to the technical field of biological medicine. The invention provides a broad-spectrum antibacterial peptide. The broad-spectrum antibacterial peptide comprises an amino acid sequence as shown in SEQ ID No. 1. The minimum inhibitory concentration of the antibacterial peptide to gram-positive bacteria, gram-negative bacteria and fungi proves that the antibacterial peptide has obvious antibacterial activity to the gram-positive bacteria, the gram-negative bacteria and the fungi. The invention also verifies the minimum inhibitory concentration of the antibacterial peptide to clinical drug-resistant bacteria. The cytotoxicity of the SL-12 disclosed by the invention is relatively weak, the SL-12 only shows obvious cytotoxicity at 200 [mu] g / ml, and the minimum inhibitory concentration of the SL-12 is 6.25-12.5 [mu] g / ml; the SL-12 has no obvious hemolytic activity when the concentration is 100 [mu] g / ml or lower, and is high in safety.

The invention relates to the field of microorganisms, and discloses lactobacillus plantarum with an antibacterial effect and application of the lactobacillus plantarum, and the preservation number of the lactobacillus plantarum is CGMCC (China General Microbiological Culture Collection Center) No.33151. The strain provided by the invention has relatively strong cholate resistance, gastric acid resistance, acid production and H2O2 production capabilities, and has a relatively strong bacteriostatic effect on common pathogenic bacteria such as staphylococcus aureus, candida albicans, escherichia coli, salmonella and helicobacter pylori; the compound can inhibit the activity of urease, interfere helicobacter pylori colonization and the like to inhibit helicobacter pylori infection or reduce the symptoms of helicobacter pylori infection and reduce the disease degree of mice with colitis, can be used for preparing microbial preparations, and has the potential of preparing drugs for preventing and / or treating diseases caused by helicobacter pylori infection.

The invention relates to the field of microorganisms, in particular to a plant lactobacillus and application thereof in bacteriostasis. Specifically, the preservation number of the plant lactobacillus LP06 is CGMCC (China General Microbiological Culture Collection Center) No. 28412. The plant lactobacillus LP06 provided by the invention can be used for inhibiting the growth of debaryomyces hansenii, candida tropicalis and penicillium rochei, and also has an inhibiting effect on super bacteria acinetobacter baumannii, pseudomonas aeruginosa, klebsiella, escherichia coli, staphylococcus aureus and listeria monocytogenes. The plant lactobacillus LP06 provided by the invention has broad-spectrum bacteriostatic ability, and bacteriostatic powder prepared from the bacterium can be used as a biological preservative for corrosion prevention of dairy products such as yoghourt, cheese and the like and other foods.

The invention relates to the field of cubilose peptides, in particular to preparation and application of cubilose glycopeptides capable of preventing and assisting in treating gynecological inflammation and gastrointestinal inflammation. The invention provides cubilose glycopeptide which comprises cubilose peptide, sialylated O-glycan and sialylated N-glycan, and the cubilose peptide is connected with the sialylated O-glycan and / or the sialylated N-glycan. The cubilose glycopeptide provided by the invention has unique sialylated O-glycans and N-glycans, has unique biological activity and functions and synergistic effect compared with the cubilose glycopeptide without N-glycans or O-glycans and non-sialylated cubilose peptides, and forms and enhances the inhibition effect on pathogens and the antiviral effect; therefore, the compound has unique advantages in the aspect of preventing and treating related problems. The sialic acid binding type cubilose glycopeptide has stronger antibacterial activity, especially has an inhibition effect on pathogens such as candida albicans and helicobacter pylori, and also has an antiviral effect.

The invention relates to the field of microorganisms, and discloses lactobacillus plantarum and application of the lactobacillus plantarum in preparation of a medicine for preventing and / or treating vaginitis, and the preservation number of the lactobacillus plantarum is CGMCC No.33152. The lactobacillus plantarum provided by the invention has a relatively strong bacteriostatic effect on common vaginal pathogenic bacteria such as Atortoria, staphylococcus aureus, Candida albicans, Escherichia coli and Gardneria, and also can reduce the infection degree of the pathogenic bacteria by inhibiting colonization and reproduction of the pathogenic bacteria; in addition, the proinflammatory factor level in sick vaginitis tissues is reduced, and the anti-inflammatory factor level is improved.

The invention relates to lactobacillus crispatus LC30 for preventing and treating female genital tract infection and application of the lactobacillus crispatus LC30. The lactobacillus crispatus LC30 is preserved in the China General Microbiological Culture Collection Center with the preservation number of CGMCC NO.31923. The lactobacillus crispatus LC30 has good hydrogen peroxide production capacity and adhesion capacity, has a strong inhibition effect on main vaginitis pathogenic bacteria, and can be used for preventing and treating female genital tract infection. The composition is effective to nutritional pathogenic bacteria, and can also reduce form transformation and biological membrane formation of the pathogenic bacteria and prevent and treat drug resistance; besides, the fermentation product can reduce the content of pathogenic bacteria metabolites, regulate the secretion of cytokines and achieve the effect of relieving inflammation, so that the fermentation product can be used for preparing products for preventing and treating genital tract pathogenic bacteria infection, preventing and treating vaginitis and / or removing pudendum peculiar smell.

The invention relates to lactobacillus gasseri FMTA1125B with the effect of preventing, relieving or treating vaginitis and application of the lactobacillus gasseri FMTA1125B. The lactobacillus gasseri FMTA1125B is classified and named as lactobacillus gasseri, and the preservation number of the lactobacillus gasseri FMTA1125B is CGMCC No.34292. The lactobacillus gasseri FMTA1125B has the effects of preventing, relieving or treating vaginitis and the application of the lactobacillus gasseri FMTA1125B. The bacterium can produce beneficial components such as lactic acid, gamma-aminobutyric acid and hydrogen peroxide through metabolism so as to regulate the genital tract environment and improve the health degree; and the traditional Chinese medicine composition has relatively good bacteriostasis and sterilization effects on common vaginal pathogenic bacteria such as escherichia coli, staphylococcus aureus, gardnerella vaginalis, candida albicans, neisseria gonorrhoeae and the like. Therefore, the lactobacillus gasseri FMTA1125B strain can be used for preparing a preparation with the effect of improving related genital tract diseases such as vaginitis.

The invention provides lactobacillus crispatus, which is preserved in the general microbiological center of the China Committee for Culture Collection of Microorganisms on February 7, 2023, and the preservation number is CGMCC (China General Microbiological Culture Collection Center) No. 26503. The bacillus subtilis can play a relatively strong role in inhibiting pathogenic bacteria such as gardnerella vaginalis, escherichia coli and staphylococcus aureus at the same time, and also has a certain role in inhibiting candida albicans, two-way proteurella and Atortoria vaginalis. Therefore, the lactobacillus crispatus has the potential of maintaining the environment in the vagina to be faintly acid and improving the mucosal immunity and infection resistance of a host, and can be used for preventing and treating vaginal infection and inflammation, and maintaining, improving or recovering the steady state of the environment in the vagina.

The invention relates to the technical field of microorganisms, and provides lactobacillus mucilaginosus for maintaining genital tract health and preventing genital tract infection and application of lactobacillus mucilaginosus. Fermented mucus lactobacillus for maintaining genital tract health and preventing genital tract infection is named as FMTA1113H and is preserved in China General Microbiological Culture Collection Center (CGMCC) on April 22, 2025, the preservation address is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing, and the preservation number is CGMCC NO.34291. The invention further discloses a preparation method of the fermented mucus lactobacillus for maintaining genital tract health and preventing genital tract infection. According to the technical scheme, the problems that female genital tracts are prone to infection and relapse is prone to occurring after infection in the prior art are solved.

The invention discloses an antibacterial peptide and application thereof, and belongs to the technical field of biology. The antibacterial peptide with an inhibition effect on various clinically common pathogenic microorganisms is obtained, and the antibacterial peptide comprises gram-negative bacteria such as escherichia coli, klebsiella pneumoniae, pseudomonas aeruginosa, acinetobacter baumannii, vibrio parahaemolyticus, salmonella gallinarum, salmonella typhimurium and enterobacter sakazakii, and gram-positive bacteria. The antibacterial peptide provided by the invention can be used as an antibacterial peptide, such as staphylococcus aureus, listeria monocytogenes and bacillus cereus, and the antibacterial peptide provided by the invention is novel in structure and easy to prepare.

According to the method, an antibacterial peptide sequence design framework is designed based on protein language model supervised fine tuning and human feedback reinforcement learning, a multiple screening framework is designed, and specifically, an antibacterial peptide design and screening model and a fine tuning mode of the model are developed through an innovative calculation method and a comprehensive analysis process; the method effectively solves the problems of low antibacterial peptide design and screening efficiency, insufficient accuracy, single optimization dimension and the like in the prior art, and an efficient, accurate and flexible new method is provided for research and development of the antibacterial peptide.

A breast milk-derived Limosilactobacillus fermentum MSJK0025 capable of improving the intestinal flora condition and the use thereof. The breast milk-derived Limosilactobacillus fermentum MSJK0025 is deposited in the China General Microbiological Culture Collection Center with a deposit number of CGMCC No. 26426. The breast milk-derived Limosilactobacillus fermentum is a new strain isolated from breast milk of healthy puerperae, and is referred to as Limosilactobacillus fermentum MSJK0025. The strain has a good antibiotic sensitivity and stable inheritance of traits, has a good tolerance to acid, bile salts and artificial gastric / intestinal fluid, and has a fast growth rate and good safety. Furthermore, the strain has a strong intestinal colonization capability and can effectively inhibit intestinal pathogenic bacteria such as Escherichia coli, Staphylococcus aureus, Salmonella typhimurium and Candida albicans, but has no inhibitory effects on intestinal probiotics such as Lactobacillus and Bifidobacterium.

The invention discloses hydrogel loaded with antibacterial polypeptide as well as a preparation method and application of the hydrogel. The preparation method of the hydrogel comprises the steps that antibacterial polypeptide and polyethylene glycol dimethacrylate are subjected to a cross-linking reaction, the hydrogel can be obtained, and the antibacterial polypeptide is obtained through polymerization synthesis of a cationic CBL monomer compound and an HBL monomer compound; the hydrogel has remarkable sterilization and anti-biofilm effects, and in-vitro cytotoxicity shows that the antibacterial polypeptide hydrogel product has no inhibition effect on normal cell growth; when the hydrogel dressing is used as a hydrogel dressing and is combined with novobiocin for use, more than 99% of antibacterial effect is achieved in a diabetes wound infection model and a fungal psoriasis infection model; and when being used as a hydrogel preparation to be combined with fluconazole, the compound has the effect of inhibiting growth of more than 99% of fungi in an animal vaginitis model.

Provided is an antibacterial peptide having an amino acid sequence X1KRFKKFFX2KLKKWV-NH2, wherein X1 is selected from any one or of amino acids A, C, D, E, F, G, H, K, L, N, M, P, Q, R, S, I, V, W, Y, and T or is absent; and X2 is an amino acid having an aromatic side chain or an amino acid having an alkaline side chain. In view of defects such as poor gastrointestinal fluid stability of antibacterial peptides in the prior art, a brand-new sequence design scheme and preparation method for an antibacterial peptide are provided. By means of a complete or partial D-amino acid substitution or structural derivatization of a peptide sequence, a series of antimicrobial peptides having stronger antibacterial activity and gastrointestinal stability as compared with the prior art are obtained, such that the antibacterial peptides have a wider application range and higher development potential value.

The invention relates to a water-soluble carbon chain substance for adjusting transmembrane transport and fluidity of a cell membrane, and preparation and application thereof. The water-soluble carbon chain substance comprises a carbon chain originally having certain water solubility, and the structure of the water-soluble carbon chain substance comprises at least one or more hydrophobic carbon chain parts and one or more hydrophilic groups or residues; the hydrophobic carbon chain part is coupled with water-soluble molecules to form a high-hydrophilicity compound; the water-soluble carbon chain can be used for preventing and treating infections including viruses, bacteria and fungi; anti-aging; the occurrence of neurodegenerative diseases such as Alzheimer's disease is prevented and reduced; by reducing the non-specific phagocytosis of the nano-drug by cells, the effect of the nano-drug on a target focus is enhanced.

The invention relates to a radix scutellariae self-assembled nanoparticle and terbinafine co-loaded nanoparticle as well as a preparation method and application thereof, and belongs to the technical field of drug nanoparticles. The preparation method comprises the following two steps: preparing scutellaria baicalensis self-assembled nanoparticles, and preparing the scutellaria baicalensis self-assembled nanoparticles and terbinafine co-loaded nanoparticles. The co-loaded nanoparticles are prepared by the preparation method. The invention also discloses application of the co-loaded nanoparticles in treatment of dermatophytosis. The invention has the following advantages: the saturation solubility of baicalin (BCN) and terbinafine (TBF) is increased; the dissolution rate of the terbinafine (TBF) is obviously improved; the antibacterial effect of the TBF is improved; hypha growth, biomass generation and spore germination of three kinds of trichophyton of trichophyton rubrum, trichophyton mentagrophytes and microsporum canis can be inhibited.

The invention relates to a bifidobacterium animalis subsp. Lactis B7 as well as a composition and application thereof, and belongs to the technical field of microorganisms, the bifidobacterium animalis subsp. Lactis B7 is preserved in the China Center for Type Culture Collection on April 19, 2024, and the preservation number is CCTCC NO: M2024734. The bifidobacterium animalis subsp. Lactis B7 is named as Bifidobacterium animalis subsp. Lactis B7, the composition is named as Bifidobacterium animalis subsp. Lactis B7, and the composition is named as Bifidobacterium animalis subsp. Lactis B7. The invention also discloses application of the B7 fermentation composition in preparation of medicines for preventing and treating ulcerative colitis, constipation and constipation-type ulcerative colitis. According to the bifidobacterium animalis subsp. Lactis B7, high-yield short-chain fatty acid and indolepropionic acid are achieved, sulforaphane is generated through glucoraphanin, intestinal tract movement is improved, ulcerative colitis or inflammatory bowel disease activity index DAI and weight loss caused by the disease activity index DAI are effectively relieved, mouse colon injury is remarkably relieved, and mucosa layers are protected; the effects of resisting inflammation, inhibiting pathogenic bacteria and improving the intestinal barrier function are achieved.

Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.

The invention provides an antibacterial peptide and application thereof, and belongs to the technical field of biological medicine. Based on bioinformatics and an AI technology, a novel broad-spectrum antibacterial peptide is expected to be screened from tick (hard tick shoulder) genomes, and the antibacterial peptide has antibacterial activity on bacteria (including clinical drug-resistant strains) and fungi, does not have obvious cytotoxicity and hemolytic activity, and is an important candidate molecule of anti-infective drugs. In the embodiment of the invention, the minimum inhibitory concentration of the antibacterial peptide on gram-positive bacteria, gram-negative bacteria and fungi is verified, and the antibacterial peptide is proved to have obvious antibacterial activity on the gram-positive bacteria, the gram-negative bacteria and the fungi. The invention also verifies that the minimum inhibitory concentration of the antibacterial peptide to clinical drug-resistant bacteria is equivalent to the minimum inhibitory concentration of the antibacterial peptide to standard strains, and verifies that the antibacterial peptide can be used as a broad-spectrum antibacterial peptide and is named as SL-15.

The invention relates to the technical field of microorganisms, and provides lactobacillus crispatus FMTA1145 C with a bacteriostatic effect and application of the lactobacillus crispatus FMTA1145 C. The lactobacillus crispatus FMTA1145 C is preserved in the China General Microbiological Culture Collection Center (CGMCC) on April 22, 2025, the address of the lactobacillus crispatus FMTA1145 C is No.3, No.1 yard, Beichen West Road, Chaoyang District, Beijing, and the preservation number of the lactobacillus crispatus FMTA1145 C is CGMCC NO.34293. The lactobacillus crispatus FMTA1145 C has the advantages that the lactobacillus crispatus FMTA1145 C has the antibacterial effect, and the lactobacillus crispatus FMTA1145 C has been preserved in the China General Microbiological Culture Collection Center (CGMCC) on April 22, 2025; according to the technical scheme, the problem that the existing lactobacillus crispatus has a poor treatment effect on female vaginal diseases in the prior art is solved.

The present invention relates to the screening of functional probiotics and its application, and specifically provides a strain of Lactobacillus casei RH99 that produces high extracellular polysaccharides and relieves vaginitis, and its preservation number is CGMCC No.32108. The Lactobacillus casei can inhibit the growth of Gardnerella, Candida albicans, and Peptostreptococcus and their biofilm generation ability; the extracellular polysaccharides produced by it have a significant promoting effect on the biofilm formation of Lactobacillus casei itself. RH99 is inoculated into the vagina, and its strain, the metabolites (exocellular polysaccharides) produced, and the core monosaccharide (D-mannitol) can all inhibit the colonization of pathogenic bacteria and promote the colonization of lactic acid bacteria; and RH99 can also relieve vaginitis by inhibiting inflammatory factors. It can be seen that RH99 can inhibit the growth of pathogenic bacteria + inhibit biofilm formation + inhibit pathogenic bacteria adhesion + inhibit the level of inflammatory factors through key core metabolites, and realize the all-round inhibition of four-in-one.

The invention provides a cyclic peptide as well as a preparation method and application thereof. The cyclic peptide has an amino acid sequence # imgabs0 # represented by formula (1) (wherein X is a Lys residue modified with a fatty acid molecule, and a line connecting Arg and Lys represents an amide bond. The cyclic peptide prepared by the invention has wide antifungal activity and antibacterial activity on drug-resistant bacteria; meanwhile, the biotoxicity and the protease degradation resistance are high, and the in-vivo antibacterial effect of the cyclopeptide can be prolonged. The cyclic peptide can be applied to preparation of anti-bacterial and anti-fungal infection drugs, and can be used as an excellent substitute drug or an auxiliary drug of existing antibiotics. The method for preparing the cyclic peptide is simple, raw materials are easy to obtain, and industrial production can be achieved.

The invention discloses a dual-mechanism antibacterial photosensitizer as well as a preparation method and application thereof, and relates to the technical field of biomedical photoelectric functional materials. The invention relates to a triphenylamine derivative, which can realize fluorescence imaging of bacterial or fungal infection by utilizing fluorescence characteristics, can generate active oxygen under illumination to play a photodynamic therapy role, is suitable for preparing photodynamic therapy preparations and developing antibacterial materials, and can also be applied to the fields of environment and public health and tumor treatment. The problems that an existing photosensitizer is insufficient in broad spectrum, different in fungus drug resistance mechanism, limited in single treatment effect and the like can be effectively solved, and the photosensitizer has wide application prospects.

The invention discloses an arbutin derivative 6-O-Caffeoylbutin as well as a preparation method and application of the arbutin derivative 6-O-Caffeoylbutin. The structural formula of a 6-O-Caffeoylbutin compound is shown as a formula (I): # imgabs0. The invention also discloses application of the arbutin derivative (6-O-Caffeoylbutin) disclosed by the invention in preparation of an antioxidant preparation. According to the invention, the 6-O-Caffeoylbutin extracted for the first time shows excellent antioxidant activity, the ability of the 6-O-Caffeoylbutin to remove ABTB < + > free radicals is stronger than that of ascorbic acid and beta-arbutin, and a material basis is provided for development of novel antioxidants.

The invention relates to the technical field of feed formulas, and particularly discloses a natural mixed feed additive and a preparation method thereof. The natural mixed feed additive comprises the following raw materials in parts by mass: 4-7 parts of vitamin E, 5-15 parts of beta-carotene, 10-16 parts of soybean oil, 20-35 parts of deionized water, 5-8 parts of modified probiotic microcapsules and 1-5 parts of an emulsifier, wherein the modified probiotic microcapsules contain sodium alginate-pectin composite microencapsulated probiotics; the preparation method comprises the following steps: heating 10-16 parts of soybean oil to 35-45 DEG C, then adding 4-7 parts of vitamin E and 5-15 parts of beta-carotene, and stirring; adding 1-5 parts of an emulsifier into 20-35 parts of deionized water, heating to 45-55 DEG C, stirring, and then slowly adding into the mixed solution obtained in the step S1; 5-8 parts of modified probiotic microcapsules are added, and stirring is conducted for 8-12 min under the condition of 100-200 r / min. The natural mixed feed additive disclosed by the invention has the advantage that the defect that the feed additive still has defects in the aspect of reducing intestinal diseases of animals can be overcome.

The present disclosure relates generally to antimicrobial gels. In particular, the present disclosure relates to an antimicrobial gel comprising a eutectic solvent and a gelling agent which can be used as a drug delivery vehicle for antimicrobial agents, including for the topical delivery of antimicrobial agents to the skin of a subject. The present disclosure also relates to processes for preparing the antimicrobial gel, and to methods, uses and compositions comprising the antimicrobial gel.

The invention discloses a double-response collagen-based conductive hydrogel, a medicine and a preparation and application method of the double-response collagen-based conductive hydrogel. The preparation method of the double-response collagen-based conductive hydrogel comprises the following steps: carrying out chemical modification on polysaccharide through 3-aminophenylboronic acid, and then carrying out sodium periodate oxidation treatment to obtain a dialdehyde polysaccharide grafted aminophenylboronic acid copolymer; the preparation method comprises the following steps: performing hydrazide modification on collagen through adipic acid dihydrazide, and performing free radical polymerization with aniline to obtain a hydrazide collagen grafted polyaniline copolymer; the dialdehyde polysaccharide grafted aminophenylboronic acid copolymer and the hydrazide collagen grafted polyaniline copolymer are subjected to crosslinking, and the double-response collagen-based conductive hydrogel capable of responding to glucose and the pH value is obtained. Compared with single-response conductive hydrogel, the hydrogel can specifically respond to the microenvironment of chronic diabetic wound surfaces and release antibacterial and anti-inflammatory drugs, and high-quality healing of chronic wounds such as diabetic foot ulcers and the like is promoted.

The invention belongs to the technical field of biological medicine, and particularly relates to a luliconazole composition containing essential oil, cream and a preparation method and application of the luliconazole composition. The present application provides a composition containing tea tree essential oil that promotes the skin permeability of luliconazole and has an antibacterial function, the tea tree essential oil and luliconazole form a synergistic antifungal effect, the transdermal absorption is enhanced by a natural terpene component, and the irritation to the skin is significantly reduced.

The invention discloses an eel antibacterial polypeptide Ajaspkidin and application thereof in preparation of an anti-vibrio composition. The amino acid sequence of the eel antibacterial polypeptide Ajaspkidin is shown as SEQ ID NO.01. The invention further discloses an application of the eel antibacterial polypeptide The zebra fish antibacterial peptide has the characteristics of excellent molecular characteristics, broad-spectrum antibacterial activity, efficient bactericidal ability, high thermal stability, high biological safety, anti-infection effect on zebra fish infected by vibrio vulnificus, capability of remarkably improving the survival rate of bred animals and the like, and has a wide application prospect.

The invention relates to the field of biotechnology and female health care, in particular to a stachyose composition for promoting micro-ecological regulation of lactobacillus and application of the stachyose composition, and the composition comprises stachyose and pharmaceutically acceptable auxiliary materials. The stachyose is used as prebiotics to selectively promote proliferation and colonization of the lactobacillus crispatus, the combination of 1%-5% of the stachyose and 0.1%-0.5% of the lactic acid can promote proliferation of the lactobacillus crispatus, the lactobacillus crispatus is one or more of the lactobacillus crispatus, the lactobacillus plantarum and the lactobacillus acidophilus, and the combination of 1%-5% of the stachyose and 0.1%-0.5% of the lactic acid can inhibit gardnerella and candida albicans. The stachyose composition disclosed by the invention is in the form of slow-release gel and bath foam; the composition can be used for treating or preventing bacterial vaginitis, colpitis mycotica and related symptoms, has the advantages of no antibiotics, no drug resistance, high safety and the like, and is suitable for the fields of vagina local nursing and micro-ecological regulation.